A marketing campaign appears to misuse endocrinologist Robert Lustig’s name, MIT references and manipulated footage to sell Glycopezil, without credible evidence of clinical testing or authorisation.
A marketing campaign using Dr. Robert Lustig’s name is promoting a supposed diabetes breakthrough that does not withstand scrutiny. Malwaretips says the pitch relies on a fabricated recommendation, a borrowed MIT connection and a product called Glycopezil, while other scam-watch sites have described the same material as an AI-assisted deception built around false celebrity and doctor endorsements.
Lustig is a real endocrinologist known for his public work on metabolic health, which helps explain why the presentation may seem convincing at first glance. But the distinction that matters is simple: a genuine medical career does not amount to approval of an unrelated supplement, and an academic background at MIT does not prove that the university developed, tested or endorsed a specific bottle of drops. The problem is not that Lustig lacks credentials; it is that the advert appears to misuse them.
According to Malwaretips, the promotion mixes a diabetes concern, a recognised expert and institutional references into a story that sounds authoritative before steering viewers towards a purchase. The site says the campaign also leans on a dramatic claim involving a “red vitamin” and a parasite-related explanation for diabetes, but offers no credible evidence that the finished product matches any legitimate research or authorised medical recommendation.
Jordan Liles, writing about Glycopezil, similarly reported that the scheme uses deepfake-style footage and manipulated content featuring public figures including Lustig and Sanjay Gupta to manufacture trust. Other critical reviews of Glycopezil say the marketing relies on celebrity-style endorsements, vague scientific language and the absence of independent verification, while the brand’s own material presents the supplement as a natural blood-sugar support product without resolving those concerns.
That gap between presentation and proof is the key issue. A proper medical or scientific claim would need an identifiable study, the exact formulation tested, the dose, the participants and the outcome measured. Instead, the campaign appears to use a familiar face, a familiar university and a familiar health fear to create the impression of authority. But a familiar name is not evidence, and a polished sales page is not the same thing as a clinical trial or an institution’s own announcement.
For consumers, the safest response is to treat the recommendation as unauthorised and to avoid changing diabetes care on the strength of the advert. Anyone who already acted on it should keep the order records, preserve the claims made in the pitch and speak to the clinician overseeing their treatment before making any further changes. As Malwaretips notes, the immediate priority is to protect established care while separately pursuing any cancellation, refund or payment dispute through the merchant and payment provider.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
